The SURPASS-CVOT trial is a phase 3, randomized, double-blind cardiovascular outcomes trial that will assess tirzepatide for both non-inferiority and superiority against dulaglutide. For dulaglutide, this effect is already proven: According to the Trulicity website, the drug may be used in adults with type 2 diabetes to reduce the risk of major cardiovascular events (problems having to do with the heart and blood vessels) such as death, heart attack, or stroke in people who have heart disease or multiple cardiovascular risk factors. How do I know which medication is right for me
How the Gala GLP-1 Process Actually Works: Four Steps, One Critical Disclaimer Gala's website describes a four-step process
At Shapiro Legal Group, PLLC, we take Ozempic, Wegovy, Rybelsus, Mounjaro, and Trulicity claims on a contingency fee basis
Recognizing the source of that hesitation helps patients make informed, confident decisions about their health
Oprea, A